Premium
The type‐II NADH:quinone oxidoreductase (NDH‐2) from Staphylococcus aureus has been recognized as a potential target for antimicrobial therapy. Structural and biochemical studies reveal that NDH‐2 is a dimeric protein with distinct binding sites for the two substrates (NADH and quinones). Kinetic studies identify quinone reduction as the rate limiting step. For details, see the article by Sena et al . on pp. 272–288 of this issue.
Publication year - 2015
Publication title -
molecular microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 247
eISSN - 1365-2958
pISSN - 0950-382X
DOI - 10.1111/mmi.13228
Subject(s) - quinone , biology , oxidoreductase , staphylococcus aureus , limiting , antimicrobial , microbiology and biotechnology , biochemistry , bioinformatics , enzyme , genetics , bacteria , mechanical engineering , engineering